Lowest Price Guaranteed
Pages
234
Last Updated
June 2026
View Count
16431
The global KRAS market size, valued at USD 476 million in 2024, is projected to reach USD 557 million in 2025 and USD 3,894 million by 2035, representing a CAGR of 21% during the forecast period.
 |
To learn more about this report, request a free sample copy
Over the years, cancer has been reported as one of the leading causes of death across the world. Every year American Cancer Society publish data about cancer patients and fatalities annually, indicating rise in cancer cases worldwide. According to the report published by American Cancer Society, in 2025, around 2,041,910 new cancer cases and 618,120 cancer deaths has been estimated to occur in the US. Healthcare experts reported that late diagnosis of cancer is the primary reason for high mortality rates. It is evident that late diagnosis results in delayed treatment and the chances of survival of a patient become low. Since a large number of population with oncological indications remain affected, researchers continue to explore advance technologies for early diagnosis and targeted cancer therapeutics to improve patient outcomes.
 |
 |
 |
It is worth noting here that drug developers engaged in this field are emphasizing the development of targeted therapies against various oncogenic mutations that are responsible for cancer development and progression. One of these oncogenic mutations is KRAS, which was identified to be associated with nearly 30% of cancer in humans. Notably, KRAS mutation is a common error in protein inside the normal cell. It acts as an information center for signals inside the cells that result in cell growth. When mutations occur in KRAS, it starts signaling excessively and cells begin to grow uncontrollably, ultimately leading to cancer. These cancer-causing mutations were first identified in Kirsten Rat Sarcoma virus; hence the name KRAS.
 |
 |
 |
With advances in technologies such as next generation sequencing and genome profiling techniques, clinicians are able to detect KRAS mutations and design therapeutic drugs that can specifically target these mutations. It is worth highlighting here that researchers who are active in this domain are currently evaluating various drug candidates to target these RAS specific mutation genes and some even succeeded in receiving approval from the USFDA. There are currently two approved KRAS inhibitors, Amgen’s Lumakras and Mirati Therapeutics’ (acquired by Bristol Myers Squibb) Krazati.
 |
 |
 |
Owing to their high target efficacy and safety profile, researchers are evaluating the aforementioned drugs to target multiple solid tumor indications such as lung cancer and colorectal cancer. Currently, various pharmaceutical companies are leveraging opportunities to develop KRAS targeting therapies either independently or in partnership with other industrial leaders. As the drug developers are accelerating their research and development activities to find novel therapeutics for targeting these oncogenic mutations, we believe the KRAS market will grow substantially during the forecast period.
The market study report provides comprehensive details on the key players who are presently active in this domain across various segments as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2025 | USD 557 Million | |
| Market Size 2035 | USD 3,894 Million | |
| CAGR (Till 2035) | 21% | |
| Target Disease Indication |
|
|
| Types of Molecule |
|
|
| Type of Therapy |
|
|
| Type of Therapeutic Area |
|
|
| Route of Administration |
|
|
| Type of Development Phase |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of KRAS market report was to estimate the current market size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
Additionally, the market report features the likely distribution by target disease indication (acute myeloid leukemia, colorectal cancer, head and neck cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, Phelan-Mcdermid syndrome, and skin cancer), type of molecule (small molecules and biologics), type of therapy (monotherapy and combination therapy), type of therapeutic area (oncological disorders and genetic disorders), route of administration (intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral and subcutaneous), type of development phase (Phase I / II, Phase III and approved), geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America), and Leading Players.
To account for the uncertainties associated with the development of KRAS inhibitors and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.
On the basis of target disease indication, the global KRAS industry is segmented into acute myeloid leukemia, colorectal cancer, head and neck cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, Phelan-Mcdermid syndrome and skin cancer. According to our projection, currently non-small cell lung cancer dominates the market and is poised to capture 92% of the market share by 2035. KRAS mutations are largely seen in patients with lung cancer. Furthermore, the growing prevalence of non-small cell lung cancer and rising approval of KRAS G1C inhibitors has provided a new focal point to the pharmaceutical companies for driving research in this field. It is important to highlight here that the regulatory agencies are also encouraging the development of targeted therapies for treating patients of lung cancer with identifiable molecular targets such as KRAS.
However, in the future, colorectal and pancreatic cancer will show substantial growth and are likely to grow at a higher CAGR during the forecast period. This can be attributed to the growing emphasis of industrial players on developing tailored therapies for treating patients with colorectal and pancreatic cancer that occur due to KRAS mutations.
The global KRAS market is segmented on the basis of type of molecules into biologics and small molecules. According to our projection, presently small molecules hold the highest share of the market. The approved KRAS inhibitors, Lumakras and Krazati, are small molecules, taken orally. The high potential to penetrate the targeted sites and interact directly with transmembrane target protein contributes to the efficacy of small molecules. Furthermore, enhancement in the drug delivery methods and improvement in the structure-based small molecules to optimize the response at targeted sites and overcome the resistance interlinked with first generation inhibitors are contributing to the largest share of small molecules.
It is important to highlight here that small molecules will continue to grow at a higher CAGR during the forecast period owing to the ongoing research for improving target specificity to treat patients with KRAS mutations-based cancer.
Based on the KRAS market trends, type of therapy is segmented into monotherapy and combination therapy. Among these, combination therapy accounts for the highest share of the market. This can be attributed to the fact that combination therapy has shown higher efficacy in targeting KRAS mutations in patients suffering from a wide range of cancer. Furthermore, the growing approval of drug combinations for the treatment of patients with cancer is associated with KRAS mutations.
The global market for KRAS inhibitors is categorized on the basis of therapeutic areas into oncological disorders and genetic disorders. It is interesting to highlight here that presently oncological disorders dominate the market and are poised to hold 99% share of the overall market by 2035. This can be attributed to the fact that KRAS has shown positive outcomes for the treatment of patients with a wide range of cancer. In addition, the growing research on KRAS mutations that result in non-small cell lung cancer, pancreatic cancer and skin cancer is likely to be the key reason for dominance of oncological disorders segments.
Furthermore, the growing approval of therapeutic drugs for targeting KRAS mutations has contributed to the significant share of this segment. Driven by the ongoing research and rising approval of drugs, this segment will continue to remain dominant and is likely to grow at a highest CAGR during the forecast period.
Based on the type of administration route, the global market is segmented into intravenous, intramuscular, intradermal, intraocular, intraperitoneal, oral and subcutaneous. According to our KRAS market analysis, currently the oral route of administration occupies the highest share (70%) of the market, driven by the growing preferences of convenient and non-invasive drug delivery by geriatric population. Furthermore, the successful development of orally administered small molecule inhibitors for targeting KRAS has contributed to the highest share of this segment. However, with growing emphasis on targeted drug delivery, intravenous will grow at a higher CAGR during the forecast period.
The global KRAS market value is distributed based on the key geographical region into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Among these, currently North America is dominating the market and is anticipated to capture 78% share of the overall market. This dominance is due to the growing risk of cancer in this region, and ongoing research for the development of advanced therapeutics that can potentially target specific mutations that result in cancer. Furthermore, the rising collaborations between industrial players for the identification of personalized medicine to target KRAS mutations is likely to be the key reason for the highest share of this region. While North America is leading the market, this industry is likely to experience the fastest growth driven by the increasing investment in healthcare infrastructure.
The “KRAS Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the drug developers.
To date, several KRAS inhibitor drugs have been approved by the USFDA. For instance, in January 2025, Amgen today announced the USFDA approval for LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. This approval has been based on the pivotal Phase 3 CodeBreaK 300 study. The accelerated approval for the KRAS inhibitors have catered to the attention of industrial players for innovations.
Presently, the market landscape features the presence of several well-established players who hold technological expertise for the development of advanced KRAS inhibitors. Key companies are currently engaged in several acquisitions, mergers and partnerships aiming to gain competitive advantages for enhancing their product portfolio. Bristol Myers Squibb (BMS) acquired Mirati Therapeutics and gained hold of its oncology pipeline in January 2024. Overall, the market will remain competitive throughout the projected period offering enormous opportunities for industrial stakeholders to take strategic initiatives and make a robust presence.
With growing incidence of cancer globally, a surge has been noticed for the requirement of effective therapeutic drugs. However, the present focus of key player is on identifying the novel drugs that can potentially target KRAS mutations specifically in cancers such as pancreatic cancer and colorectal cancer where these types of mutations are high. Furthermore, the increasing research to understand the KRAS mutational biology and potential innovations for drug developments are the key drivers of the KRAS market.
The pipeline for KRAS inhibitors has few drugs in late-stage clinical development which are anticipated to provide competition to the currently approved drugs. The next approval in the market is expected to be for Verastem Oncology’s One such drug is Roche’s divarasib which started phase III clinical trial in September 2024, a head-to-head trial against the approved Lumakras and Krazati. The primary completion of the trial is expected in September 2026. Another drug in phase III clinical trials is Revolution Medicine’s RMC-6236 for treatment of patients with previously treated metastatic pancreatic ductal adenocarcinoma. The approval of pipeline KRAS inhibitors will drive the market growth over the forecast period.
Despite of high demand, KRAS market also witness several challenges that may impede the growth of market for therapeutic drugs targeting KRAS mutations. One of the potential challenges is the complex biology of KRAS mutations which can create difficulty in finding appropriate targets. Furthermore, the variability of KRAS mutations across different form of cancers also create challenges in determining high target specific drugs. In addition to complex biology, KRAS mutations may develop drug resistance to different type of selective therapies and chemotherapies, which may create difficulty in designing drugs for targeting cancerous cells. It is worth noting here that some RAS inhibitors may show low bioavailability which results in slow absorption of therapeutics.
Some of the potential growth factors that are propelling the growth of this market include emerging technologies for the development of targeted therapies and supportive guidelines. Notably, technologies such as genome editing technologies, organs-on-chips and sequencing technologies enable researchers to identify the targeted genes and determine the mutations on molecular level. These technologies offer better insight into the development of targeted therapies. Furthermore, regulatory agencies have offered a flexible framework for the development of innovative targeted therapies to target KRAS mutations. In addition, the increasing collaboration between industrial players for the development of target specific KRAS inhibitors is a key growth factor which is expected to drive market growth at a steady rate.
The market for KRAS is currently valued at USD 557 million and is estimated to reach USD 3,894 million by 2035. In 9M 2025, Amgen reported 6% increase in sales year-over-year to $90 million in the second quarter of Lumakras. The KRAS inhibitors at this stage have yet to perform as per the expectations of the market investors.
It is worth noting that North America is currently holding the largest share of the market driven by the high demand for targeted therapies to treat patients suffering from cancer, as per KRAS market forecast. Moreover, the key players established in this region and continuously putting efforts to develop advance KRAS drugs. Driven by the growing demand for advanced targeted therapies, the KRAS market will continue to grow at a CAGR of 17% during the forecast period.
Examples of key companies engaged in development of KRAS inhibitors (which have also been profiled in this market report; the complete list of companies is available in the full report) include Amgen, GlobeImmune, Jacobio Pharmaceuticals, Mirati Therapeutics, Novartis (discon), Onconova Therapeutics, Targovax and Verastem Oncology. This market report includes an easily searchable excel database of all the companies developing KRAS targeting therapies worldwide.
Several recent developments have taken place in the field of KRAS market. We have outlined some of these recent initiatives below.
Amongst other elements, the market research report features: